ArticleFrontiers in oncology2026
Ultrasound-based deep learning radiomics for the differential diagnosis of benign and malignant subpleural pulmonary lesions.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ultrasound Radiomics in Pediatric Imaging: Current Applications, Challenges, and Future Directions Toward Clinical Implementation.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to develop an ultrasound-driven clinical deep learning radiomics (CDLR) model for the differential diagnosis of benign and malignant subpleural pulmonary lesions (SPLs), with the goal of guiding personalized treatment and minimizing unnecessary interventions. Methods: A retrospective analysis was conducted on 609 SPL patients from July 2020 to February 2024 at Guangxi Medical University. The dataset was divided into training (487 cases) and validation (122 cases) cohorts. Prior to ultrasound-guided lung mass biopsy, 1561 radiomics (Rad) features were extracted from every ultrasound image, alongside 128 deep transfer learning (DTL) features after dimensionality reduction and compression based on ResNet-50. Feature selection was performed, followed by the development of a deep learning radiomics (DLR) model using a Support Vector Machine (SVM), which was then used to derive the model's feature. Clinical data were analyzed through univariate and multivariate logistic regression, generating the clinical features. The DLR and clinical features were integrated using SVM to create the CDLR model for differentiating benign and malignant SPLs. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), and its clinical utility was assessed Results: The CDLR model demonstrated high accuracy in distinguishing benign and malignant SPLs. The AUC values for the training and validation set were 0.987 and 0.924, respectively. Notably, the CDLR model outperformed clinical, standalone Rad, DTL, and DLR models in the validation cohort. The model also achieved the highest sensitivity (0.871), specificity (0.897), and accuracy (0.877). Grad-CAM visualization highlighted key regions of interest within ultrasound images, and SHAP analysis identified the contributions of clinical, deep learning, and radiomics features. Conclusion: The ultrasound-based CDLR model provides a robust tool for differentiating benign and malignant SPLs, offering superior diagnostic performance compared to existing ultrasound diagnostic criteria. This model is valuable for early lung cancer screening and can reduce unnecessary biopsies or surgeries for pulmonary masses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.